Michelle Sidor
Company: Alchemab Therapeutics Ltd
Job title: Director of Neuroscience
Seminars:
Mining Patient Resiliency-Associated Targets for Novel Antibody Therapeutics: Discovery of the CD33 antibody, ATLX-1088 11:30 am
Sequencing the B cell repertoire from resilient patient populations to look for protective auto-antibodies in an unbiased manner Identifying resilient autoantibodies to uncover novel targets and pathways for target discovery Harnessing the neuroprotective activity of microglia within the 1088 program as a novel antibody therapeuticRead more
day: Discovery Track AM